Rifampin (Page 5 of 5)
Meningococcal Carriers
Adults: For adults, it is recommended that 600 mg rifampin be administered twice daily for two days.
Pediatric Patients: Pediatric patients 1 month of age or older: 10 mg/kg (not to exceed 600 mg per dose) every 12 hours for two days.
Pediatric patients under 1 month of age: 5 mg/kg every 12 hours for two days.
Preparation of Extemporaneous Oral Suspension
For pediatric and adult patients in whom capsule swallowing is difficult or where lower doses are needed, a liquid suspension may be prepared as follows:
Rifampin 1% w/v suspension (10 mg/mL) can be compounded using Simple Syrup (Syrup NF):
1. Empty the contents of four Rifampin 300 mg capsules or eight Rifampin 150 mg capsules onto a piece of weighing paper.
2. If necessary, gently crush the capsule contents with a spatula to produce a fine powder.
3. Transfer the rifampin powder blend to a 4-ounce amber glass or plastic (high density polyethylene [HDPE], polypropylene, or polycarbonate) prescription bottle.
4. Rinse the paper and spatula with 20 mL of syrup, and add the rinse to the bottle. Shake vigorously.
5. Add 100 mL of syrup to the bottle and shake vigorously.
This compounding procedure results in a 1% w/v suspension containing 10 mg rifampin/mL. Stability studies indicate that the suspension is stable when stored at room temperature (25 ± 3°C) or in a refrigerator (2-8°C) for four weeks. This extemporaneously prepared suspension must be shaken well prior to administration.
HOW SUPPLIED
Rifampin Capsules, USP, 150 mg opaque orange capsules printed in white on one half of
the capsule in radial print “Rifampin 150” and on the other half in radial print “VP/015”
Bottles of 30 (NDC 61748-015-30)
Unit Dose Boxes of 100 (NDC 61748-015-11)
Rifampin Capsules, USP, 300 mg opaque orange capsules printed in white on one half of
the capsule in radial print “Rifampin 300” and on the other half in radial print “VP/018”
Bottles of 30 (NDC 61748-018-30)
Bottles of 60 (NDC 61748-018-60)
Bottles of 100 (NDC 61748-018-01)
Unit Dose Boxes of 100 (NDC 61748-018-11)
Storage: Store at 20-25°C (68-77°F) [See USP Controlled Room Temperature]. Store in a
dry place. Avoid excessive heat. Protect from light. Dispense in a tight, light-resistant
container as defined in the USP using a child-resistant closure.
REFERENCES
- Clinical Laboratory Standards Institute, Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard CLSI Document M24-A, Vol. 23, No. 18, CLSI, Villanova, PA, 2003.
- Clinical Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically — Eighth Edition. Approved Standard CLSI Document M7-A8, Vol. 29, No. 2, CLSI, Villanova, PA, January 2009.
- Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Disk Susceptibility Tests — Tenth Edition. Approved Standard CLSI Document M2-A10, Vol. 29, No. 1, CLSI, Villanova, PA, January 2009.
- Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement, CLSI Document M100-S20, Vol. 30, No. 1, CLSI, Villanova, PA, January 2010.
Manufactured for:
VersaPharm Incorporated
Marietta, GA 30062-2260
Manufactured by:
West-ward Pharmaceutical Corp.
Eatontown, NJ 07724
Repacked by:
H.J. Harkins Company, Inc.
Nipomo, CA 93444
Revised October 2011
PRINCIPAL DISPLAY PANEL
NDC 61748-018-30
Rifampin Capsules, USP
300 mg
Rx Only
30 Capsules
RIFAMPIN rifampin capsule, coated | ||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||
|
Labeler — H.J. Harkins Company, Inc. (147681894) |
Registrant — H.J. Harkins Company, Inc. (147681894) |
Establishment | |||
Name | Address | ID/FEI | Operations |
H.J. Harkins Company, Inc. | 147681894 | repack, relabel |
Revised: 01/2012 H.J. Harkins Company, Inc.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.